Anemia of Chronic Kidney Disease

Hematology
8
Pipeline Programs
2
Companies
7
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
4
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 4 programs with unclassified modality

On Market (1)

Approved therapies currently available

Akebia Therapeutics
VAFSEOApproved
vadadustat
Akebia Therapeutics
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]oral2024

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Akebia Therapeutics
Akebia TherapeuticsCAMBRIDGE, MA
4 programs
4
1
Erythropoiesis-Stimulating AgentPhase 31 trial
VadadustatPhase 3Small Molecule1 trial
VadadustatPhase 3Small Molecule1 trial
vadadustatPhase 3Small Molecule1 trial
Active Trials
NCT06901505Active Not RecruitingEst. Aug 2026
NCT05082584WithdrawnEst. Oct 2026
NCT06520826RecruitingEst. Jun 2026
+1 more trials
Akros Pharma
Akros PharmaNJ - Princeton
3 programs
3
JTZ-951Phase 11 trial
JTZ-951Phase 11 trial
JTZ-951, 14C-JTZ-951Phase 11 trial
Active Trials
NCT01971164Completed29Est. Jul 2014
NCT02581124Completed10Est. Apr 2016
NCT02805244Completed6Est. Sep 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Akebia TherapeuticsErythropoiesis-Stimulating Agent
Akebia TherapeuticsVadadustat
Akebia Therapeuticsvadadustat
Akebia TherapeuticsVadadustat
Akros PharmaJTZ-951, 14C-JTZ-951
Akros PharmaJTZ-951
Akros PharmaJTZ-951

Clinical Trials (7)

Total enrollment: 45 patients across 7 trials

NCT06901505Akebia TherapeuticsErythropoiesis-Stimulating Agent

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Start: Jul 2025Est. completion: Aug 2026
Phase 3Active Not Recruiting

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents

Start: Jan 2025Est. completion: Oct 2026
Phase 3Withdrawn

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease

Start: Jan 2025Est. completion: Oct 2026
Phase 3Withdrawn

Vafseo Outcomes In-Center Experience

Start: Nov 2024Est. completion: Jun 2026
Phase 3Recruiting
NCT02805244Akros PharmaJTZ-951, 14C-JTZ-951

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

Start: Jun 2016Est. completion: Sep 20166 patients
Phase 1Completed

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

Start: Oct 2015Est. completion: Apr 201610 patients
Phase 1Completed

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

Start: May 2013Est. completion: Jul 201429 patients
Phase 1Completed

Related Jobs in Hematology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 45 patients
2 companies competing in this space